Search results
Showing 1036 to 1050 of 1364 results for social care
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued Reference number: GID-TA10596
Agenda and papers of the NICE public board meeting on 10 December 2025
Agenda and papers of the NICE public board meeting on 22 March 2023
Agenda and papers of the NICE public board meeting on 20 March 2024
Agenda and papers of the NICE public board meeting on 13 December 2023
Agenda and papers of the NICE public board meeting on 19 July 2023
Benralizumab for previously treated severe nasal polyps [ID1659]
In development Reference number: GID-TA10818 Expected publication date: TBC
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued Reference number: GID-HST10038
Nintedanib for untreated malignant pleural mesothelioma [ID1424]
Discontinued Reference number: GID-TA10359
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]
Discontinued Reference number: GID-TA10464
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)
NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Discontinued Reference number: GID-TA10711
NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions
reducing alcohol consumption in people who misuse alcohol compared with standard care? Any explanatory notes(if applicable) Why this is...